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FIG. 1A 
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FIG. 2A 
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POLYAMINE-POLYAMINE AND 
POLYAMINE-PROTEIN TRANSPORT 
INHIBITOR CONJUGATES AND THEIR USE 
AS PHARMACEUTICALS AND IN 
RESEARCH RELATING TO POLYAMINE 
TRANSPORT 
FIELD OF THE INVENTION 
The present invention is directed to polymeric conjugates 
of substances which are normally actively transported into 
cells or protein or polypeptide conjugates of such nonnally 
transported substances and the use thereof to inhibit uptake 
of such normally transported substances. The present inven 
tion is more particularly directed to polymeric conjugates of 
polyamines, and conjugates of polyarnines and proteins or 
polypeptides and the use thereof to inhibit the cellular 
uptake of polyarnines. 
BACKGROUND OF THE INVENTION 
The endogenous polyamines, in particular, putrescine 
(l,4~butanediamine), spermidine (N-[3-aminopropyl]-1,4 
diarninobutane) and spermine (N,N‘-bis-[3-aminopropyl]-1, 
4-butane-diamine) have been the subject of increasing 
research, due to the growing appreciation of their physi— 
ological importance. These polyarnines have regulatory 
roles in tissue growth and interact with nucleic acids, as well 
as exhibiting a variety of eifects upon macromolecular 
synthesis, expression and metabolism (Tabor et al., Ann. 
Rev. Biochem, 30, 597 (1961); Janne et al., Biochem. 
Biophys. Acta, 473,241, (1978); and Tabor et al., Ann. Rev. 
Biochem, 45,285 (1976)). 
Accounts on the biochemistry, regulation and potential 
functions of polyarnines may be found in recent review 
articles (Tabor et al., Ann. Rev. Biochem, 53,749 (1984); 
Pegg et al., Ann. J. PhysioL, 243, C212 (1982); Pegg, 
Biochem J., 234, 249 (1986); Seiler et al., Acza Biochem. 
Biophys. Hung, 23, 1 (1988); and, Seiler et a1, Int. J. 
Biochem, 22, 211, (1990)) from which most of this back 
ground discussion is excerpted. 
Polyarnine homeostasis and adjustment of the intracellu~ 
lar concentrations to physiological requirements are regu~ 
lated by both synthetic and catabolic reactions. De novo 
biosynthesis can in principle be substituted by polyamine 
transport from the environment. 
In cells lacking amine oxidases which oxidatively deami‘ 
nate polyarnines, the release of intracellular polyarnines is 
essential for the regulation of polyamine cellular concentra 
tions. Currently available evidence suggests that Nl-Nz 
diacetylspermine may also ful?ll regulatory requirements. 
The actual signals which control polyamine release are not 
known. However, there exists strong evidence in the scien 
ti?c literature that the proportion of N‘-acetylspermine and 
N'-acetylspern1idine which remains intracellular and which 
is oxidatively cleaved into spermidine and putrescine is 
controlled by outward transport (Seiler, J. Physiol. Pharma 
col., 65, 2034 (1987)). 
In vivo studies involving the metabolism of labeled 
polyarnines have shown that polyarnines may be taken up by 
tissues from the circulation. It is further well known that 
some tissues exhibit a high demand for polyamines. 
Examples of such tissues include the prostate (Clark et al., 
J. Nucl. Med, 16, 337 (1975)), tumor cells (Volkow et al., 
Science, 221,673 (1983)) and normal but rapidly proliferat 
ing cells (Janne et al., Acta Chem. Scand, 20, 1174 (1966); 
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Seiler et al., Brain Res., 22, 81 (1970)). Enhanced uptake of 
1‘*C-labeled polyarnines by tissues with depleted polyamine 
stores has repeatedly been observed (Chaney et al., Life Sci., 
32, 1237 (1983); Huston et al., Cancer Res., 44, 1034 
(1984)). 
Recently, much research has been undertaken to charac 
terize and understand the particular transporters which con 
trol polyamine uptake in mammalian cells. Early work on 
polyamine transport related to bacteria and other microbia 
and is reviewed in Tabor et al., Pharmac. Rev, 16, 245 
(1964) and Bachrach, “Function of Naturally Occurring 
Polyamines,” pp. 51-52, Academic Press, NY. (1973). 
Other papers describing polyamine transport in speci?c 
microbia are also available in the literature (Davis et al., 
Arch. Biochem. Biophy, 267,479 (1988) and Kashiwagi et 
al., J. East, 165, 972 (1986)). 
Polyamine uptake systems in mammalian cells resemble 
the uptake systems of amino acids. Accordingly, most 
researchers studying polyamine transport have used research 
strategies which have had prior success in characterizing 
amino acid uptake. 
To date there still exists no complete understanding of 
polyamine transport systems in mammalian cell lines. How 
ever, from what is disclosed in the literature, it appears that 
polyamine transport is energy and temperature dependent, 
and saturable. Therefore, it seems that it is a carrier-medi 
ated transport system. An exception is polyamine transport 
into perfused rabbit lung or lung slices which appears not to 
be energy dependent or Na‘“ activated, suggesting that 
polyamine uptake into the lungs of this species may instead 
occur via diffusion (Rao et al., Biochem. Biophys. Acta, 966, 
22 (1988)) rather than an active carrier system. Polyamine 
uptake in lungs of other species, including rats, is saturable 
and energy-dependent (Rannels et a1). 
Available evidence suggests that macromolecular synthe 
sis of RNA and prornins is required to adapt polyamine 
transport to enhanced polyamine requirement (Martin et al., 
Inl’l. Symp. Polyamines in Biochem. Clin. Res., Sorrento 
(Italy), Abst. p. 67 (1988). Most cells appear to have a single 
transporter for putrescine, spermidine and spermine as 
shown by competitive studies. However, some cells appear 
to have more than one pathway for polyamine uptake 
wherein each transporter comprises a di?ferent at?nity for 
putrescine, spermidine and spermine (Kumagai et al., Am. J. 
Phys., 254, G81 (1988); Minchin et al., Int’l. Symp. 
Polyamines Biochem. Clin. Res,, Sorrento (Italy),Abst. p. 67 
(1988); Byers et al., Am. J. PhysioL, 252, C663 (1987); 
Feige et al., Biochem. Biophys. Acta, 846, 93 (1985); and De 
Srnedt et al., Biochem. Biophys. Acza, 1012, 171 (1989)). 
The a?inity for the carrier increases from putrescine to 
spermidine and spermine with published Km values in the 
low M range. Polyamine transport is observed in the 
absence of sodium; however, the increase of sodium to 
physiological concentrations (116 mM) usually increases the 
transport rate by 60%. Dissipation of the sodium gradient by 
ionophores has been shown to inhibit the sodium-dependent 
portion of polyamine uptake. 
While high a?inity sodium-activated transport is usually 
observed, some cell types exhibit sodium-independent 
polyamine uptake. For example, in LLC-PKl renal epithe 
lial cells both the sodium-activated and the sodium-inde 
pendent transport systems were saturable. By contrast, in 
adrenocortical cells the sodium independent transport sys 
tem was not saturable and preferentially transported sper— 
mine (Feige et al., Biochem. Biophys. Acta, 846, 93 (1985)). 
Activation of polyamine transport into mammalian cells 
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by thiols (glutathione, dithiothreitol) and inhibition by thiol 
reagents (p-chloromercuribenzene sulfonate, N~ethylmale 
imide) has been studied by many researchers. The results 
obtained by these researchers suggest that the sodium 
activated transporter requires thiol groups to maintain active 
conformation. 
The amino acid uptake pathways are generally regarded 
as diiferent from polyarnine transporters systems. However, 
a number of amino acids (asparagine, glutamine, serine, 
alanine and ot-(methylarnino)isobutyric acid) stimulate at 
0.5 mM concentration putrescine uptake into a neuroblas 
toma cell line (Rinehart et al., J. Biol. Chem., 259, 4750 
(1984)) and that some basic amino acids exhibit a very weak 
inhibitory effect on polyamine uptake. 
The polyamine transporter does not appear to be speci?c 
for putrescine, spermidine or spermine. Therefore, it is likely 
that polyamine analogs are transported by the same system. 
Some researchers have compared a series of homologous 
diamines and triarnines in relation to their ability to inhibit 
competitively the uptake of labelled putrescine, spermidine 
and spermine by L1 210 leukemia cells. 1,7-Heptene diarnine 
followed by l,8~octanediamine and 1,6-hexanediamine were 
most potent among the diarrrines, while triarnines were 
generally more effective as uptake competitors. Maximum 
inhibition was achieved using amines having comparable 
chain lengths to spermine and spermidine. This is consistent 
with the understanding in the art that the recognition site of 
the polyarnine transporter contains at least three negatively 
charged groups in a distance corresponding to the distance 
between the positively charged nitrogen atoms of spermi 
dine, presumably in its most stable all-trans con?guration. 
(Gordon-Smith et al., Biochem. Pharmacol, 32, 3701, 
(1983)). 
The primary amine groups of the polyamines seem to be 
essential for uptake. For example, N-alkyl substituents on 
the terminal arrrino groups of putrescine, spermidine or 
spermine decrease the ability of these compounds to com 
petitively inhibit uptake. Also, substituents (F, Cl, OH, CH3) 
in the last two positions of the carbon chain of putrescine 
reduce polyarnine uptake. 
Methylglyoxal-bis(guanylhydrazone) (MGBG), an anti 
leukemic drug which inhibits S-adenosylmethionine decar 
boxylase and which exhibits a structure highly similar to 
spermidine shares the polyamine transport system. The 
potent cytotoxicity of this compound thereby afforded 
researchers a selection method for identifying Chinese ham 
ster ovary cells incapable of MGBG and polyamine trans 
port (Mandel et al., J. Cell. Physiol, 97, 335 (1978). Genetic 
studies indicate that more than one gene locus is involved in 
MGBG uptake by these cells (Heaton et al., J. Cell. Physiol, 
136, 133 (1988)). 
Also, it is believed that such polyamine transport mutants 
should play a major role in identifying genes involved in 
polyamine transport, for studying the regulation of transport, 
and for studying the role of polyamine transport in prolif 
erating cells and in some related disease conditions such as 
cancer. 
For example, Ask et al. recently studied increased survival 
of Ll2l0 leukemic mice by preventing utilization of extra 
cellular polyarnines using an Ll210 leukemic cell line 
(Ll2lO-MGBG’) de?cient in polyamine transport. Their 
results indicated that leukemic mice bearing the polyamine 
uptake mutant cells exhibited a cure rate of 33% when 
polyamine synthesis was blocked by DFMO. By contrast, 
rrrice having non-mutant polyarnine transport Ll2l0 cells 
only had a two day increase in survival time after similar 
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DFMO treatment (Ask et al., Cancer Lett., 66, 29 (1992)). 
The polyamine uptake system has been implicated in the 
uptake of other drugs as well. For example, paraquat (N,N‘ 
dimethyl-4,4'-dipyridylium) has been shown to inhibit the 
uptake of MGBG, putrescine and spermidine, but with no 
apparent eifect on spermine uptake (Smith et al., Biochem. 
Pharmac., 30, 1053 (1981)). 
Also, some researchers have attempted to design cyto 
toxic drug conjugates which are similar in structure to 
endogenous polyamines so that they are transported by the 
polyarnine transport system. For example, Holley et a1. 
recently synthesized a series of 2- and S-nitroimidazole 
polyarnine conjugates which were apparently transported by 
the polyarnine transport system. Of the compounds tested, 
the 2-nitroimidazole-po1yamine conjugates were the most 
potent inhibitors of spermidine uptake (Holley et a1, Bio 
chem. Pharmacol. 43,763, (1992)). 
Also, several bipyridinium, tetrapyridinium and hexapy 
ridinium quaternary salts have been found to be potent 
inhibitors of putrescine uptake into B16 melanoma cells 
which have previously treated with di?uoromethylornithine, 
with the potency of inhibition being apparently directly 
related to the number of quaternary centers (Minchin et al., 
Biochem. J., 262, 391 (1989). 
Some inhibitors of polyamine uptake have been discov 
ered which are structurally unrelated to polyamines. For 
example, the cationic peptide melittin and another calmodu 
lin antagonist, 1.3~dihydroxy-l-(4-methyl)- 4H,6H-pyrrolo 
[1,2-9][4,l]-benzoxazepin-4-y1)methyl]-4-piperidinyl]-2H 
benzimidazol- 2-one (CG 59373B) inhibits putrescine 
uptake into human prostate cells. Tri?uoropiperazine, a 
calmodulin antagonist and protein kinase C inhibitor also 
inhibits polyamine uptake as does the protein kinase C 
inhibitor H7 (l-(5-isoquinolinylsulfonyl)-2-methyl-pipera 
zine). Also, treatment of leukemia cells with phorbyl esters 
activates proteinase kinase C and has been shown to enhance 
spermidine uptake into murine leukemic cells. It therefore 
appears that protein kinase C may play a role in polyamine 
transport. 
Various factors are believed to affect the uptake of 
polyamines into mammalian cells including (i) availability 
of polyamines in vivo, (ii) intracellular polyamines, (iii) the 
sialic acid coating on the cell membrane, and (iv) the growth 
state of the particular cells. 
The availability of polyamines in the circulation is 
believed to be important in polyamine transport. Putrescine 
and spermine blood concentrations are low in comparison to 
sperrrridine (Claverie et al., Anticancer Res., 7, 765, (1987)). 
This is surprising given that the electrostatic binding of 
spermine to negatively charged groups is higher than for 
spermidine and putrescine. Accordingly, one would expect 
the concentration of free spermine to be extremely low, 
particularly in light of the fact that red blood cells have a 
negative surface charge and e?iciently bind polyamines. 
Further evidence of the importance of spermidine uptake is 
the fact that the Vmax of spermidine is higher than that of 
spermine, despite its lower a?inity to the transporter. 
The level of intracellular polyamines is also believed to 
a?ect polyamine uptake. Depletion of intracellular 
polyamines has been found to generally enhance polyamine 
uptake several-fold. As in the case of circulating 
polyamines, the concentration of free intracellular 
polyamines is probably involved in regulation of uptake. 
As noted above, the sialic acid coating on cell membranes 
is believed to have some effects on polyamine transport. The 
removal of N-acetylsialic acid from the surface of murine 
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leukemia cells by incubation with neurarninidase enhances 
spermidine uptake. Re-sialated cells regain normal transport 
rates (Khan et al., Biochem. Arch, 5, 161 (1989)). It is 
believed by some researchers that the sialic cell surface 
coating nonspeci?cally binds positively charged polyamines 
via the carboxyl group of the sialic acid residues thereby 
diminishing effective concentration of transport substances 
at the transporter site. 
Polyamine transport is also believed to be important for 
the ability of cells to adapt to changes in polyamine require 
ments. Enhanced cell growth rates are usually accompanied 
by both enhanced intracellular de novo synthesis and 
enhanced uptake of polyamines. 
Trophic stimuli, including hormones and growth factors, 
have been observed to enhance polyamine transport rates 
(Pohjanpelto, J. Cell. Biol, 68, 512 (1976), DiPasquale et 
al., Exp. Cell. Res., 116, 317 (1978)). In these studies 
stimulation of human ?broblasts to cell proliferation by 
serum or epidermal growth factor was followed by an 
18~100 fold increase of ornithine decarboxylase activity. 
Also, stimulation of mouse mammary glands with insulin 
caused the increase of VW for spermidine and prevented 
effects thereof (Kano et al., J. Biol. Chem, 251, 2795 
(1976)). However, it is unknown whether the hormone 
induced formation of the carrier or decreased carrier inac 
tivation. 
Some studies have shown that transformed cells transport 
polyamines better than their normal counterparts. However, 
in at least one study involving EJZ-ras transfected cells 
polyamine turnover was enhanced but transport rates 
remained una?ected. In contrast, N-myc transfection 
enhanced polyamine uptake with no affect on biosynthesis 
(Chang et al., Biochem. Biophys. Res. Comm, 157, 164 
(1988). Thus, there exists circumstantial evidence that 
polyamine uptake and synthesis may be regulated by dif 
ferent genes. Perhaps not unexpectedly, cells exhibiting 
reduced growth rates have been observed to decrease 
polyamine uptake. For example, cells approaching cell con 
?uency because of high cell density decrease polyamine 
uptake. Also, when cells are induced to diiferentiate and 
therefore reduce their rate of proliferation, their demand for 
polyamine has been found to diminish. 
As discussed above, cellular concentrations of 
polyamines are regulated by at least two important path 
ways. The ?rst, and best understood, involves de novo 
biosynthesis. The rate of cellular polyamine synthesis is 
governed by the activity of the enzyme ornithine decarboxy 
lase (ODC) which catalyzes the conversion of the amino 
acid ornithine to the diarnine putrescine. Putrescine, in turn, 
is then convened sequentially to spermidine and spermine by 
two other enzymes. The role of ODC in regulation of cell 
polyamine contents and its potential suitability as a phar 
macological target has been facilitated by the development 
of DEMO, (ot-di?uoro-methylornithine), a highly selective 
and potent inhibitor of this enzyme. In some instances, 
inhibition of ODC with DFMO is highly effective in deplet 
ing cell polyamine cell contents and arresting cell prolifera 
tion. However, in other instances the cells seem to use 
compensatory pathways to maintain adequate polyamine 
concentrations. Results of human clinical trials with DFMO 
have, in general, been disappointing. Though the drug is 
bene?cial in treating some non-neoplastic diseases (e.g., 
infectious conditions), its therapeutic ef?cacy in cancer 
appears to be limited. 
The reason for the poor results with DEMO is believed to 
be attributable to the polyamine transport system of cells. As 
15 
20 
25 
40 
45 
50 
55 
65 
6 
discussed supra, along with de novo polyamine synthesis, 
cells are apparently capable of regulating and accumulating 
polyamines across their plasma membrane via an energy~ 
dependent transport system. Work by the present inventors 
and others suggests that most cells express at least two 
pathways for polyamine uptake. The ?rst comprises a non 
selective pathway for putrescine, spermidine and spermine 
and the second comprises a pathway which is selective for 
spermine and spermidine. Both pathways are markedly 
increased when ODC activity is depressed, either by patho 
logic changes or by treatment with DFMO, and are thereby 
able to compensate for decreased de novo polyamine syn 
thesis. Because there exist no pharmacological agents which 
selectively inhibit polyamine transport, the suitability of this 
pathway as a pharmacological target has as yet not been 
adequately established. 
As discussed above, most previous attempts to design 
inhibitors of polyamine transport have focused on 
polyamine analogues with a few exceptions involving sev 
eral calmodulin antagonists and protein kinase C inhibitors. 
However, the previously examined molecules have either 
lacked speci?city and/or exhibited unacceptable toxicity. 
Thus, there still exists a substantial need in the art for 
e?ective polyamine transport inhibitors which selectively 
inhibit the transport of speci?c polyamines while not exhib 
iting unacceptable toxicity and while not a?ecting the trans— 
port of other transported substances. Also, there exists a 
need in the art for a convenient and reproductive method for 
obtaining transport inhibitors of desired substances. 
OBJECTS OF THE INVENTION 
It is an object of the invention to obviate the problems 
observed with previous transport substance inhibitors, e.g., 
non-speci?city and toxicity. 
It is another object of the invention to provide novel 
inhibitors of transport of substances normally actively trans 
ported by cells which selectively inhibit the uptake of the 
targeted substance into such cells, which comprise poly 
meric conjugates of the transported substance or a protein or 
polypeptide conjugated to the transported substance. 
It is a further object of the invention to use such novel 
transport inhibitors of targeted substances which comprise 
polymers of transported substances or polypeptide or pro 
tein-transported substance conjugates in vitro to study the 
role of the uptake of the targeted substance which is nor 
mally actively transported on various cellular processes and 
cell functions. 
It is another object of the invention to administer such 
novel transport inhibitors of normally transported sub 
stances which comprise polymeric conjugates of transported 
substances or protein or polypeptide-transported substance 
conjugates in vivo to treat disease conditions which involve 
transport of the particular transported substance. 
It is a speci?c object of the invention to provide novel 
polyamine transport inhibitors which comprise polymers of 
polyamines or polyamine-protein or protein conjugates 
which selectively inhibit uptake of a targeted polyamine and 
which do not exhibit undesirable toxicity. 
It is another speci?c object of the invention to use novel 
polyamine transport inhibitors which comprise polyamine 
polymers or polyamine-protein or polypeptide conjugates 
which selectively inhibit cellular uptake of targeted 
polyamines in vitro to study the effect of the particular 
targeted polyamine on cellular functions. 
It is yet another object of the invention to administer novel 
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polyarnine transport inhibitors which comprise polyamine 
polymers or polyamine-protein or polypeptide conjugates 
selectively inhibit the transport of targeted polyamines for 
treating disorders wherein polyarnine transport is involved 
in the disease condition, e.g., cancer. 
It is yet another object of the invention to provide novel 
pharmaceutical compositions for treating disease conditions 
relating to the transport of a targeted substance which 
contain an effective amount of a novel inhibitor comprising 
a polymer of the transported substance or a transported 
substance-protein or polypeptide conjugate which selec 
tively inhibits the cellular uptake of the targeted substance. 
It is still another object of the invention to provide novel 
pharmaceutical compositions for treating diseases wherein 
polyarnine uptake is involved in the disease condition com 
prising adrninistering an e?fective amount of the subject 
novel polyarrrine transport inhibitors which comprise poly 
mers of polyamines or polyamine-protein or polypeptide 
conjugates. 
BRIEF DESCRIPTION OF THE INVENTION 
Previous attempts to design substances which inhibit the 
cellular uptake of normally transported substances have in 
general focused on synthesizing analogues of the normally 
transported substance. A case in point are the previously 
synthesized polyarnine transport inhibitors which were in 
general substances having structural similarity to trans 
ported polyamines. 
The rationale behind such an approach is that if the 
particular analogue is similar enough in structure to the 
nonnally transported substances it will be transported into 
the cell by the same cell transport system. Therefore, it 
should provide for the competitive inhibition of uptake of 
the targeted substance. 
While this approach works in some instances, it is fraught 
with many inherent problems. For one, it is sometimes 
dif?cult to synthesize an analogue of the targeted transported 
substance which is capable of being effectively transported 
into the cell by the same transport system and which 
competitively inhibits the transport of the targeted sub 
stance. Another problem is that the particular analogue, even 
if transported, may exhibit undesirable toxicity which pre 
vents its in vivo usage. Examples of such compounds 
include antineoplastic agents such as methylglyoxalbis(gua 
nylhydrazone) (MGBG) which while mimicking the struc 
ture of endogenous polyamines and inhibiting the transport 
thereof possess a high degree of toxicity. 
Yet another problem with the design of effective inhibitors 
involves designing substances which speci?cally inhibit the 
uptake of a targeted substance while not inhibiting the 
uptake of other non-targeted substances. This is essential for 
in vitro studies if one is to be able to elucidate the cellular 
functions a?ected by the particular targeted substance. Also, 
it is important for in vivo usage in the use of such inhibitors 
for treating disease conditions wherein one desires to inhibit 
uptake of an undesirable targeted substance while not pre 
venting uptake of other substances which may be essential 
for well being. 
The present inventors have discovered two novel classes 
of transport inhibiting substances which differ fundamen 
tally from previous transport inhibitors. These inhibitory 
substances comprise a modi?cation of a well-accepted 
approach for constructing conjugates between endogenous 
chemicals that are normally actively transported into cells 
and low-molecular weight drugs as a means for enhancing 
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the uptake of the drug. However, the subject transport 
inhibitors obtain a substantially diiferent function and result 
in that they are not themselves transported into cells but 
instead selectively inhibit the transport system of the cell 
which is responsible for uptake of the targeted transported 
substance, e.g., a polyamine. 
The ?rst class of transport inhibitory substances discov 
ered by the present inventors comprises polymeric conju 
gates of the targeted transported substance wherein the 
repeating units of the polymer comprise the particular tar 
geted transported substance. These moieties may be directly 
linked or may be indirectly attached using known coupling 
agents. It has been surprisingly discovered that polymers of 
a targeted normally transported substance, e. g., a polyarnine 
such as putrescine, spermine or spernridine, may be used to 
selectively block transport of the transported substance. By 
selective it is meant that these polymers do not block 
transport of non-targeted substances such as anrino acids and 
other normally transported substances. Also, these polymers 
appear to act at the level of the cell membrane and do not 
appear to enter the cells. This is in contradistinction to 
previous transport inhibitor analogues and transported sub 
stance-drug conjugates wherein the analogue or the drug 
was apparently internalized by cells. 
The second novel class of transport inhibitory substances 
discovered by the present inventors to effectively and selec 
tively inhibit transport of a targeted substance comprises 
conjugates of the targeted transported substance and a pro 
tein or polypeptide, preferably a protein or polypeptide that 
does not exhibit undesirable toxicity. It has been surprisingly 
discovered that when a normally transported substance is 
conjugated to a protein, that the resulting conjugates are 
capable of selectively inhibiting the uptake of the speci?c 
targeted substance. Also, as with the aforedescribed poly 
meric conjugates, these transported substance-protein con 
jugates apparently operate at the cell membrane and are not 
actively transported into cells. The targeted transported 
substance may be directly coupled to the particular protein, 
or may be attached by use of available coupling agents. In 
the preferred embodiment the targeted transported sub 
stances will comprise endogenous transported polyamines, 
e.g., putrescine, spermine and sperrnidine. 
Given the ability of these two classes of transport inhib 
iting substances to selectively inhibit transport of targeted 
substances they comprise utility in vitro for studying the 
cellular functions affected by a speci?c targeted transported 
substance such as, e.g., a polyamine. Also, they comprise in 
vivo utility as therapeutic agents for selectively blocking 
transport of a targeted substance involved in a particular 
disease condition. 
In the preferred embodiment the targeted transported 
substances will comprise polyamines such as putrescine, 
spermine and spermidine which are believed to be involved 
in disorders involving unrestrained cell proliferation and/or 
differentiation such as cancer, vascular diseases such as 
hypoxic pulmonary hypertension and other hypertensive 
pulmonary vascular diseases, systemic hypertensive dis 
eases, intimal hyperplasia secondary to balloon angioplasty 
(“re-stenosis”), intimal hyperplasia which may result in 
prosthetic vascular graft failure, cerebral ischernic injury, 
hyperproliferative skin diseases such as psoriasis leukemia, V 
gastric ulcer, hyperpoxic lung injury, and infectious diseases 
such as those caused by parasitic protozoa. 
However, the invention has broad utility in treating any 
disease condition wherein the onset or progression of the 
disease condition requires the uptake of a speci?c substance 
5,456,908 
by speci?c cells. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA-lC: Etfect of polyarnine-polyarnine conju~ 
gates, putrescine~putrescine (top), spermidine-spermidine 
(middle), and spermine-spermine (bottom) on uptake of free 
14C-polyarnines in cultured pulmonary artery smooth 
muscle cells. Conjugates were added to the cultures simul 
taneously with 3 M of a speci?c 1‘lC-polyarnine and 
allowed to incubate for 30 minutes after which the content 
of cell-associated radioactivity was determined. Each point 
is the mean i the standard error of at least 6 replicates. These 
data indicate that the Put-Put and Spm-Spm conjugates 
discriminate between the non-selective and selective sper~ 
midine/spermine transport systems and that the Spm-Spm 
conjugate e?’ectively blocks the import of all three 
polyamines. 
FIGS. 2A—2C: E?ect of polyamine-BSA conjugates, 
BSA-putrescine (top), spermidine-BSA (middle), and sper 
mine-BSA (bottom) on uptake of free l4C-polyamines in 
cultured pulmonary artery smooth muscle cells. Conjugates 
were added to the cultures simultaneously with 3 M of a 
speci?c 14C-polyarnine and allowed to incubate for 30 
minutes after which the content of cell-associated radioac 
tivity was determined. Each point is the mean i the standard 
error of at least 6 replicates. These data indicate that the 
Put-BSA and Spm—BSA conjugates discriminate between 
the non-selective and selective spermidine/spermine trans 
port systems and that the Spm-Spm conjugate effectively 
blocks the import of all three polyamines. 
FIGS. 3A—3C: E?’ect of polyarnine-polyarnine conju 
gates, putrescine-putrescine (top), sperrnidinespermidine 
(middle), and spermine-spermine (bottom) on uptake of free 
1‘*C-polyamines in cultured pulmonary artery smooth 
muscle cells treated with DFMO. DEMO treatment (1 mM 
for 24 hours) increased polyamine uptake approximately 
350% relative to control cells. Conjugates were added to the 
cultures after DFMO treatment and simultaneously with 3 
M of a speci?c 14C-polyamine and allowed to incubate for 
30 minutes after which the content of cell-associated radio 
activity was determined. Each point is the mean i the 
standard error of at least 6 replicates. These data indicate that 
polyarnine conjugates inhibit both transport systems in cells 
with polyarnine uptake stimulated by inhibition of de novo 
polyarnine synthesis. 
FIGS. 4A-4C: Effect of polyarnine-BSA conjugates, 
putrescine-BSA (top), spermidine-BSA (middle), and sper 
mine-BSA (bottom) on uptake of free 14C-polyarnines in 
cultured pulmonary artery smooth muscle cells treated with 
DFMO. DFMO treatment (1 mM for 24 hours) increased 
polyarnine uptake approximately 350% relative to control 
cells. Conjugates were added to the cultures after DFMO 
treatment and simultaneously with 3 M of a speci?c 
14C-polyamine and allowed to incubate for 30 minutes after 
which the content of cell-associated radioactivity was deter 
mined. Each point is the mean i the standard error of at least 
6 replicates. These data indicate that polyamine-BSA con 
jugates inhibit both transport systems in cells with 
polyarnine uptake stimulated by inhibition of de novo 
polyarnine synthesis. 
FIG. 5: Concentration-dependent cytotoxicity of Poly 
PUT conjugate in a parental lineage of human uterine 
sarcoma cells (MES-SA) and variants (DX5) expressing 
drug resistance secondary to expression of the p-glycopro 
tein. Each point is the mean i SEM of 3 replicates. 
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DETAILED DESCRIPTION OF THE 
INVENTION 
The transport inhibitory substances of the present inven 
tion may be synthesized by known methods and reagents for 
conjugating desired substances. As discussed supra, the 
conjugates between the targeted substance and the protein or 
polymers of the targeted substance may be directly linked or 
may be linked using known coupling agents. The selection 
of the speci?c coupling agent or reagent is largely a matter 
of convenience and depends upon factors including the 
available coupling agents and the speci?c targeted substance 
being conjugated and functional groups which are available 
for covalent attachment. Examples of suitable coupling 
agents include, homo and heterobifunctional coupling 
agents and reagents such as cyanogen bromide, diisocyan 
ates, dialdehydes, glutaraldehydes, carbodiimides, in par 
ticular, N-(8-maleimidobutyryloxy)-succinimide, 6‘malein 
imido-hexanoic acid N-succinimidyl ester (MHS), 
N-succinimidyl 3-(2-pyridyl dithio)propionate (SPDP), and 
l-ethyl-3-(3dimethylaminopropyl)carbodiimide. 
Methods for conjugating proteins and other organic sub 
stances and reagents for facilitating such attachment are well 
known in the art and are not a subject of the present 
invention. 
The polymeric transport inhibiting conjugates of the 
present invention will comprise a suf?cient number of 
molecules of the particular transported substance such that 
the conjugate is of a su?icient molecular weight to inhibit 
uptake of the targeted substance without itself being inter 
nalized by cells which normally uptake the targeted sub 
stance. 
The molecular weight of the subject polymeric conjugates 
of transported substances may vary from about 3,000 to 
about 500,000, more preferably from 15,000 to about 100, 
000 and most preferably from about 15,000 to about 30,000. 
For example, e?icacious polymeric polyarnine conjugates 
(which blocked transport of the particular polyarnine mono 
mer and which were apparently not themselves internalized) 
were synthesized using putrescine, sperrnine or spermidine 
as the polyarnine monomer and glutaraldehyde as the cou 
pling agent which comprised molecular weights in excess of 
15,000. 
In general, the subject polymeric conjugates will com 
prise the generic homopolymen'c structure: 
(T 5),. 
wherein TS is a normally transported substance, and n 
comprises the number of such moieties. However, as dis 
cussed supra, the TS moieties, e.g., a polyarnine, may also 
be indirectly attached using a coupling agent such as glut 
araldehyde. 
The invention further embraces heteropolymeric conju 
gates wherein the repeating monomeric units in the polymer 
comprise several different transported substances, e.g., het 
eropolymers wherein the monomeric units comprise differ 
ent polyamines. Thereby, the resulting polymeric conjugate 
should provide for the selective inhibition of cellular uptake 
of each of the different polyamines contained in the poly 
meric conjugate. 
The subject polymers of transported substances, e.g., 
polyamines, may further be conjugated to a moiety which 
provides for the targeting of the conjugates to desired cells. 
For example, the subject transported substance polymers 
may be attached to cell surface antigens, receptors, glyco 
proteins, and lectins which are expressed on cells involved 
in a particular disease condition such as cancer. 
5,456,908 
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The second novel class of novel inhibitors discovered by 
the inventors comprises conjugates of a transported sub 
stance and a protein. These conjugates will in general 
comprise the generic formula: 
wherein TS is a normally cellularly transported substance, 
e.g., involved in a particular disease condition and P com 
prises a protein or polypeptide, e.g., a biologically accept 
able protein or polypeptide. The transported substance and 
the protein or polypeptide may be directly conjugated or 
may be indirectly attached using coupling agents such as 
were described supra. Methods for conjugating proteins or 
polypeptides to desired compounds are well known to those 
of skill in the art. The particular coupling method, reagents, 
and coupling agent are again largely a matter of conve 
nience. Also, the preferred coupling agent again comprises 
glutaraldehyde. 
The protein or polypeptide to which the transported 
substance is attached will comprise any protein of suf?cient 
molecular weight to provide a conjugate which selectively 
blocks cellular uptake of the particular transported substance 
and which itself is not internalized. Also, the selected 
polypeptide should preferably not be toxic. In the preferred 
embodiments such proteins will comprise proteins of known 
application in protein conjugates for in vivo usage such as 
globulins and albumin proteins, e.g., bovine serum albumin, 
ovalburnin, key hole impact hemocyanin and human serum 
albumin. 
As stated supra, the molecular weight of the subject 
transported substance-drug conjugates should be suf?cient 
to block transport of the particular transported substance and 
be such that the conjugate is substantially non-internalized. 
The molecular weight of such conjugates will typically 
range from about 10,000 to about 500,000, preferably from 
about 50,000 to about 250,000 and most preferably from 
about 65,000 to 100,000. 
In the preferred embodiment the transported substance 
will comprise a polyamine, e.g. , putrescine, spermine or 
sperrnidine. It is also within the scope of the present inven 
tion to attach the protein or polypeptide to several different 
transported substances, e.g., polyamines, to provide a con 
jugate which inhibits the cellular uptake of several normally 
transported substances. 
As with the polymeric or transported substance conju 
gates, the subject transported substance-protein or polypep 
tide conjugates may optionally be attached to a moiety 
which provides for these conjugates to be selectively tar 
geted to desired cells, e.g., cancer cells, or the polypeptide 
or protein used for conjugation may itself provide for 
targeting to speci?c cells. 
Examples of suitable targeting moieties include cell sur 
face antigens, receptor proteins and polypeptides, single 
chain antibodies, glycoproteins, lectins, etc., which selec 
tively bind to moieties expressed on speci?c cells wherein 
the uptake of a normally transported substance is to be 
inhibited. For example, a polyamine such as sperrnidine, 
sperrnine or putrescine may be conjugated to a speci?c 
cancer cell surface polypeptide or protein to provide conju 
gates which are selectively targeted to cancer cells and 
which inhibit the uptake of the respective polyamine by such 
cells. 
The selection of a particular targeting moiety will of 
course depend upon the targeted cells. For example, if such 
targeted cells comprise cancer cells, the targeting moiety 
will preferably comprise a ligand which binds to a moiety 
expressed on the surface of such cancer cells. 
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As discussed supra, in the preferred embodiment the 
transported substance contained in the subject transported 
substance polymeric complexes or transported substance 
protein or polypeptide conjugates will comprise one or more 
polyamines or acetylatal derivatives thereof, and most pref 
erably spermine, spermidine or putrescine. 
However, the invention has broad applicability in provid 
ing conjugates which selectively inhibit the cellular uptake 
of any normally transported substance. Examples of trans 
porter pathways other than that for the polyamines contem 
plated for use in the invention include amino acids, multiple 
drug resistance transporters such as p-glycoprotein (p~gp), 
lipoproteins such low density lipoprotein (LDL), neurotrans 
mitters, scrotonia, sugars, homones, succharides, lipids, 
organic anions and cations, purines and steroids. 
The subject transported substance polymeric conjugates 
and transported substance-protein or polypeptide conjugates 
have useful in vivo and in vitro applications for selectively 
blocking cellular transport of the particular transported 
substance or substances. 
In vitro usage will include the addition of the subject 
conjugates to cell cultures which comprise a cell which 
normally uptakes the particular transported substance, 
thereby the effect of uptake of the particular substance on 
cellular functions may be delineated. In the case of 
polyamines this will be highly bene?cial since millions are 
spent in laboratories around the world to conduct studies 
relating to the cell biology of polyamines. However, prior to 
the present invention there were no pharmacological agents 
which selectively inhibited the polyamine transport system. 
Particular examples of cells wherein polyamine transport 
is believed to be important include actively proliferating 
cells such as cancer cells and vascular cells, such as pul 
monary vascular cells. For example, it is believed that 
pulmonary hypertension caused by hypoxia occurs by a 
biological mechanism involving increased polyamine trans 
port rather than increased de novo polyamine synthesis. 
Thus, the subject conjugates should facilitate further study 
of the mechanism of pulmonary hypertension and hypoxia. 
In the case of cancer, it is believed that polyamine 
transport is required for the proliferation of such cells. Also, 
it is known that many cancer cells express a specialized 
membrane pump called the “Multiple Drug Resistance" 
(MDR) transporter. This is an important system for it 
enables cancer cells to develop resistance to anti-tumor 
agents by effectively pumping the anti-tumor agent out of 
the cells. One MDR transporter has been characterized by 
previous researchers to comprise a 12 domain protein which 
spans the cell membrane. Among the numerous lZ-domain 
membrane spanning proteins known, one is a putrescine 
transporter found in bacteria. This, coupled with the fact that 
both of these transport systems are actively expressed in 
cancer cells lead the present inventors to believe that these 
systems may be related. However, the present inventors do 
not wish to be bound by any theory. 
Data contained infra supports the inventors’ belief and 
further indicates that polyamine transport results in poten 
tiation of the activity of anti-rumor agents. Therefore, the 
subject polyamine inhibitors possess utility in that they 
provide further in vitro evidence as to relatedness of these 
two transport systems. Also, they possess utility in that they 
assist in identifying in vitro anti-rumor compounds whose 
activity may be potentiated by the addition of polyamine 
transport inhibitors. 
The amount of the subject inhibitor conjugates which are 
added to a particular cell culture will comprise an amount 
which is at least su?icient to inhibit transport of the particu 
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lar transported substance, e.g., a polyamine. In general, the 
amount of the particular inhibitor conjugate added to the cell 
culture will range from about 0.001 M to about 500 M, 
preferably from about 0.1 to about 100 pM, and most 
preferably from about 0.1 M to about 20 pM. However, this 
amount will vary dependent upon the nature of the particular 
conjugate, the substance for which cell uptake is being 
inhibited, the particular cells being cultured and their capa 
bility to transport this substance. 
In the case of polyamine transport inhibitors, effective 
dosages can readily be determined by adding incremental 
amounts of the particular conjugate to cell cultures and 
assessing the effect on polyamine uptake using well known 
assays described, e.g., in Kameji et al, Amer. J. PhysioL, 256 
(Cell Physiol 25), Cl 60—Cl67, 1989; Morgan et al, Biochem 
J., 256, 413-417, 1992; Rannels et al, Am. J. Physiol, 287, 
L346-L353 1989; Kamagai et al, Amer. J. Physiol, 256, 
G905-G910, 1989; Nicolet et al, Biochem. J., 269, 629-632, 
1990. 
The subject transport inhibitor conjugates also comprise 
in vivo use both from a research and therapeutic standpoint. 
For example, the subject conjugates may be administered to 
animals, e.g., mice, rats, monkeys, and the like to study the 
effect of inhibited transport of the particular substance on a 
particular disease condition. In particular, the subject 
polyamine transport inhibitors may be administered to ani 
mals having a condition involving polyamine transport, e.g., 
cancer, vascular disorders such as pulmonary hypertension 
and other hypertensive pulmonary vascular disorders, infec 
tious disorders, hyperproliferative skin diseases, cerebral 
ischemic disorders, etc. Thereby, the in vivo role of 
polyamine transport on the particular disease condition may 
accurately be assessed. 
An important application of the subject conjugates will 
involve administration of the subject conjugates to animals 
having implanted tumors or cancer cells, e.g., rats, as 
studying the eifect of the conjugates on tumor growth and 
metastasis. Also, the subject conjugates may be administered 
in conjunction with one or more anti-tumor agents to ani 
mals having implanted tumors. Thereby, the effect on e?‘i 
cacy of the particular anti-tumor agent by the particular 
conjugate may be assessed. As discussed supra, given the 
similarities of the MDR pump and the polyamine transport 
system, and the data obtained by the present inventors, it is 
expected that the subject polyamine conjugates will poten 
tiate the el?cacy of many anti-tumor agents by reducing the 
e?iciency of the MDR pump. Also, such in vivo studies will 
provide further evidence regarding the biological link 
between these two transport systems. 
The amount of the particular conjugate which is admin 
istered to an animal will depend upon factors such as the 
particular animal, the speci?c disease condition, the particu 
lar nature of the conjugate, and the speci?c transported 
substance for which uptake is to be inhibited. In general, the 
amount administered will provide for levels of polyamines 
in the blood ranging from about 0.001 to 5000 M, prefer 
ably about 0.01 to 2000 M in the blood, and most prefer 
ably will provide for polyamines blood levels ranging from 
about 0.1 M to 200 M. 
Another important in vivo usage of the subject polyamine 
transport inhibitor conjugates will comprise administration 
to animals, e.g., rats, to evaluate the effect of these conju 
gates on the induction of ?bronectin synthesis and other 
cellular events by hypoxia in pulmonary artery smooth 
muscle cells and the effect on pulmonary arterial blood 
pressure. Such animal studies will provide in vivo evidence 
that increased polyamine transport is involved in hypoxic 
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pulmonary hypertension. Also, it should facilitate the design 
of suitable pharmacological agents for treating this condi 
tion. 
The subject transport inhibitor conjugates will be admin 
istered to animals by known methods for administering 
pharmaceuticals, e.g., orally, intranasally, intratracheally, or 
via injection routes, e.g., via intramuscular, intravenous, 
intraperiotenal or subcateneous routes. Preferably, the sub 
ject conjugates will be administered by injection, e.g., 
intraperitoneally, intravenously, intramuscularly, with the 
intravenous route being most preferred. The subject conju 
gates may be rendered into pharrnaceutically acceptable 
form by the addition of known pharrnaceutically acceptable 
carriers and excipients. 
The subject polyamine transport inhibitor conjugates may 
also be administered in combination with DFMO. This will 
enable simultaneous inhibition of polyamine transport and 
synthesis and a determination of the in vivo effects thereof, 
e.g., in a particular disease condition, such as cancer or 
hypoxic pulmonary hypertension. 
The most important in vivo application of the subject 
transport inhibitor conjugates will comprise their use as 
therapeutic agents. According to the present invention, con 
jugates may be synthesized which selectively inhibit the 
cellular uptake of any normally transported substance. 
Therefore, the subject conjugates may be used for the 
treatment of any disease condition wherein the cellular 
transport of a speci?c substance is required or is substan 
tially involved in the disease condition. 
Examples of other transported substances involved in 
disease conditions include amino acids, multiple drug resis 
tance transporters such as p-glycoprotein (p-gp), transported 
polyproteins such as low density lipoprotein (LDL), neu— 
rotransmitters, serotonin, sugars, hormones saccharides, lip 
ids, organic anions and cations, purines and steroids. 
Moreover, given their size, selectivity and mode of action 
(at the cell membrane level) the subject conjugates should 
not produce any adverse effects since they are not intemal 
ized by cells and further do not appear to block cellular 
transport of non-targeted substances. 
In the case of the exempli?ed polyamine transport inhibi 
tor conjugates, these conjugates will be used therapeutically 
in the treatment of disease conditions wherein polyamine 
transport plays a substantial role in the disease condition. 
Disease conditions wherein increased polyamine transport is 
believed to exert a signi?cant effect include diseases involv 
ing abnormal cell growth, differentiation and proliferation. 
Examples of such disease conditions include cancer, 
hypoxic pulmonary hypertension and related hypertensive 
pulmonary vascular diseases, intimal hyperplasia, secondary 
to balloon angioplasty (“restenosis”), intirmal hyperplasla 
which may result in prostnetic vascular graft failure, cerebral 
ischernic injury, hyperproliferative skin diseases such as 
psoriasis hypertensive diseases, gastric ulcers, leukemia 
systemic hypertension diseases, hyperoxic lung injury, and 
infectious diseases such as parasitic protozoan diseases. 
The subject transport inhibitor conjugates when used as 
therapeutic agents may be administered via any known 
pharmaceutical mode of administration, e.g., orally, intra 
venously (via injection), intratracheally, or rectally. Prefer 
ably, the conjugates will be administered via injection, e.g., 
intravenously, intramuscularly, subcutaneously, or intraperi 
toneally. 
The effective dosage of the subject conjugate will com 
prise dosages which are at least su?icient to inhibit transport 
of the particular targeted substance and which do not cause 
any adverse effects. Such dosages will vary dependent upon 
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factors including the speci?c disease condition being 
treated, the particular conjugate being administered, its 
biological half-life, its ability to be delivered to the targeted 
site, etc. As discussed supra, the subject conjugates may 
further comprise a targeting moiety which enhances their 
selective delivery to targeted cells, e.g., tumor cells. 
An e?‘ective therapeutic range will typically be su?icient 
to provide for polyamine concentrations ranging from 0.001 
to 5000 M, preferably ranging from about 0.01 M to 2000 
M and most preferably ranging from about 0.01M to about 
200 M. 
The subject transport inhibitor conjugatesmay be admin 
istered singularly or in combination with other drugs suit 
able in treating the particular disease condition. Also, the 
subject transport inhibitor conjugates may be administered 
together with substances which block synthesis of the par~ 
ticular transported substance so as to inhibit both the trans 
port and synthesis of a transported compound involved in 
the particular disease condition. For example, the subject 
polyamine transport inhibitor conjugates may be adminis' 
tered in combination with DFMO, which is used to treat 
disorders wherein the cellular concentration of polyamines 
is involved in the particular disorder. 
As discussed supra, an important therapeutic application 
of the subject polyamine transport inhibitor conjugates will 
involve the treatment of cancer since polyamine transport 
and synthesis is implicated in abnormal cell differentiation, 
growth and cell proliferation. 
In the treatment of cancer, the subject polyamine inhibi 
tors may further be administered in combination with known 
anti-neoplastic agents since data disclosed herein indicates 
that inhibition of polyamine transport may potentiate the 
e?icacy of some anti-neoplastic agents, most likely because 
of inhibition of the MDR transporter system. Therefore, the 
use of the subject polyamine inhibitors in combination with 
one or more anti-neoplastic agents should result in enhanced 
anti-tumor activity. 
Another important therapeutic application of the subject 
polyamine inhibitors comprises the inhibition of hypoxic 
pulmonary hypertension since data disclosed infra indicates 
that the subject conjugates inhibit ?bronectin synthesis by 
pulmonary artery smooth muscle cells, the synthesis of 
which is believed to be implicated in pulmonary hyperten 
510m. 
The following examples are offered to illustrate the 
present invention and should not be construed in any way as 
limiting its scope. 
EXAMPLE ONE 
Effect of Polyamine-Polyamine Conjugates and 
Polyamine-BSA Conjugates on Polyamine Uptake 
in Pulmonary Artery Smooth Muscle Cells 
It has been previously shown that cultured pulmonary 
artery smooth muscle cells, like may other cell types, 
express two ditferent transport systems for polyamines; a 
“nonseleetive” carrier for putrescine, spermidine and sper 
mine, and another carrier that is “selective” for spermidine 
and spermine. Based on this information, experiments were 
designed to determine whether the addition of the subject 
polyamine inhibitors, in concentrations ranging from O-ZO 
pM could block polyamine uptake by cultured pulmonary 
smooth muscle cells. Also, it was a further object of the 
experiment to determine whether the particular inhibitor 
could discriminate between the “nonselective” and “selec 
tive” polyamine transporter. 
15 
20 
25 
30 
35 
45 
50 
55 
60 
65 
16 
The two types of polyamine inhibitors tested in this 
example and the following examples comprise: (i) conju 
gates between bovine serum albumin (BSA) and either 
putrescine, spermidine or sperrnine using glutaraldehyde as 
a coupling agent; and (ii) large polyamine-polyamine poly 
meric conjugates of putrescine (Put-Put), spermidine (Spd 
Spd) and spermine (Spm-Spm) using glutaraldehyde as a 
coupling agent. The molecular weight of the synthesized 
polyamine-BSA conjugates exceeded 65,000 daltons, 
whereas the polyaminepolyamine conjugates comprised a 
molecular weight in excess of 15,000 daltons. 
Mass spectrum data has demonstrated that the most 
effective conjugate, polymeric spermine exhibited a molecu 
lar weight of about 25.5x0.5 KDa. Results of protron 
magnetic resonance, nuclear magnetic resonance, and mass 
spectral analyses indicate that the molecule exhibits a 
branched structure having relatively short extensions of 
repeating SPM-glut-SPM units off a longer polymeric SPM 
glut-SPM backbone. The SPM moieties at the termination of 
each branch and backbone appear to be unconstrained and 
free to interact with the transporter binding sites. Also, these 
conjugates were found to retain biological stability for at 
least a month after synthesis. 
Each of these polyamine-polyamine polymeric conjugates 
and the polyamine-BSA conjugates were added to pulmo 
nary artery smooth muscle cell cultures at concentrations 
ranging from 0-20 uM, along with 3 M of a speci?c 
14C-polyamine and allowed to incubate for 30 minutes. 
After this 30 nrinute period the cell-associated radioactivity 
was then measured to determine the uptake of polyamine by 
the cell culture. 
The results of these experiments are shown in FIGS. 
1A-1C and 2A-2C. FIG. 1A—C depicts the effects of the 
polyamine-polyamine conjugates on polyamine uptake, 
whereas FIGS. 2A—2C depicts the effect of the polyamine 
BSA conjugates on polyamine uptake. 
It can be seen from FIG. 1A and 2A that both Put-Put and 
Put-BSA inhibited uptake of putrescine in the pulmonary 
artery cell cultures but failed to impair the uptake of sper 
midine and spermine. 
By contrast, FIG. 1B and 2B demonstrate that both 
Spd-Spd and Spd-BSA inhibited uptake of putrescine and 
spermidine to a greater extent than spermine. 
Also, the results contained in FIG. 1C and 2C indicate that 
both forms of the sperrnine inhibitor, Spm-Spm and Spm 
BSA, inhibited uptake of putrescine, spermidine and sper 
mine. 
Control experiments were also conducted wherein the 
same concentrations of BSA were added to pulmonary artery 
smooth muscle cell cultures together with 3 M of a speci?c 
14C-polyarnine and the cultures allowed to incubate for 30 
minutes. Cell associated radioactivity was then measured. 
These results (not shown) indicated that free BSA (not 
conjugated to BSA) did not inhibit the uptake of putrescine, 
spermidine or spermine. Thus, the di?°erential, concentra 
tion-dependent e?°ects of the respective transport inhibitors 
on the uptake of the respective polyamines indicate that they 
prevent the uptake of polyamines by cultured pulmonary 
artery smooth muscle cell cultures and also that these 
inhibitors apparently interact selectively with the two 
polyamine transporters believed to exist in pulmonary artery 
smooth muscle cells as well as other cell types. 
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EXAMPLE 2 
Effect of the Subject Polyarnine Inhibitors of 
DFMO Stimulated Polyamine Uptake 
The present inventors have previously shown that the 
inhibition of polyamine synthesis in pulmonary artery 
smooth muscle cells with DFMO causes a compensatory 
increase in the activity of both the selective and non 
selective polyamine transporters. Speci?cally, putrescine, 
spermidine and sperrnine uptake increases about 3-5 fold in 
comparison to cells not treated with the polyamine synthesis 
inhibitor. This phenomenon has been noted for numerous 
other cell types and probably explains why the therapeutic 
e?icacy of DFMO is limited. Along with the induction of 
polyamine transport with DFMO, we have also found that 
culture of pulmonary artery smooth muscle cells in a 
hypoxic environment increases transport, however, not to 
the same extent as DFMO. This is important since hypoxia 
is a pathologically relevant stimulus for pulmonary hyper 
tension. 
Accordingly, similar experiments were conducted to 
determine if the induction of polyamine transport by DFMO 
and hypoxia would be prevented by the polyamine inhibitors 
of the present invention. The results of these experiments are 
shown in FIGS. 3A—3C and FIGS. 4A-4C. Speci?cally, 
putrescine-putrescine, spermidine-spermidine, spermine 
spermine, putrescine-BSA, sperrnidine-BSA and spermine 
BSA inhibitor conjugates were added in concentrations 
ranging from 0 to 20 M to pulmonary artery smooth muscle 
cell cultures which had been treated with DFMO. DFMO 
treatment consisted of the addition of 1 mM of DFMO to the 
cultures followed by a 24 hour incubation period. The 
polyamine uptake was increased relative to control cells by 
about 350%. 
After DFMO treatment and incubation, the respective 
conjugates were added in amounts ranging from about 0 to 
20 M simultaneously with 3 M of a speci?c 14C 
polyarnine and the cells allowed to incubate for 30 minutes. 
After incubation, the content of cell associated radioactivity 
was determined. The results in both FIGS. 3A—3C and FIG. 
4A-4C indicate that the subject polyamine conjugates 
inhibit both transport systems in cells wherein polyamine 
uptake has been stimulated by inhibition of de novo 
polyamine synthesis. 
Similar experiments were conducted to determine the 
effects of the subject inhibitor conjugates on hypoxic pul 
monary artery smooth muscle cells. These results are not 
shown, however, the results were identical to those obtained 
in the DFMO-treated cells. The observed results indicated 
that both types of inhibitors suppressed polyamine uptake in 
an identical manner to their actions in control cells in the 
absence of DFMO or hypoxia. 
The putrescine conjugates inhibited accumulation of 
putrescine to a greater extent than sperrnine and sperrnidine 
in DFMO cells (as shown in FIG. 3A and 4A), while the 
sperrnidine and sperrnine conjugates inhibited uptake of all 
polyamines (as shown in FIGS. 3B, 3C, 4B and 4C). Thus, 
the inhibitors are effective and retain their selectivity even 
under conditions of augmented polyamine transport. 
EXAMPLE 3 
The Effect of the Subject Polyamine Conjugates on 
Cultured Bladder Cancer Cells 
The previous examples related to the effects of the subject 
conjugates on pulmonary artery smooth muscle cells. To 
prove that these phenomena were not cell speci?c and that 
the invention has broad applicability for other cell types, in 
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particular pathologically-relevant cells, the following 
experiments were conducted. 
Speci?cally, the eifect of the subject spermine-spermine 
conjugates on two types of cultured bladder cancer cells was 
examined, the ?rst designated DXE, are resistant to anti 
tumor drugs and the second designated MESSE are sensitive 
to such anti-tumor agents. Spermine-sperrnine conjugates 
were selected since the available data indicates that this 
conjugate is an eifective and potent polyamine transport 
inhibitor for both polyamine transport systems. As shown in 
Table 1 set forth below, it was found that 20 M of the 
spermine-spermine conjugate reduced uptake of sperrnidine 
in both cell populations. Thus, the results indicate that the 
subject conjugates should have both clinical and therapeutic 
for applicability in inhibiting polyamine transport by cancer 
cells. Also, the subject conjugates should provide utility in 
vivo and in vitro for studying the relatedness of the 
polyamine transport system and the multi-drug resistance 
transport system. 
TABLE 1 
Impact of Spm-Spm Conjugate on Spermidine Uptake by Drug 
sensitive (MESSE) and Drug-resistant (DXE) 
Human Bladder Cancer Cells in Culture. 
Spermidine Uptake (uM/30 min/pg protein) 
Cell Type Control +20 M Sprn-Spm 
MESSE 5.53 i 0.35 0.33 i 0.14 
DXE 1.00 i- 0.03 0.32 i 0.02 
EXAMPLE 4 
Effect of the Subject Conjugates on Uptake of 
Amino Acids 
As discussed supra, there are some parallels between the 
transport of polyamines and amino acids. Accordingly, the 
present inventors considered the possibility that the subject 
polyamine transport inhibitors may not be selective, i.e., 
they may inhibit the uptake of naturally occurring amino 
acids as well as polyamines. 
To prove that this was not occurring, the effect of the 
subject polyamine-BSA and polyamine-polyamine conju 
gates on the uptake of the non-metabolizable amino acids, 
speci?cally methyl amino isobutyric acid and lysine was 
examined in cultured pulmonary artery smooth muscle cells. 
These amino acids were selected because lysine is positively 
charged like the subject polyamines and also because both 
these amino acids use diiferent transport systems which are 
distinct from the polyamine transport system. 
The results of this experiment are found in Tables 2A and 
2B set forth on the following page: 
TABLE 2A 
Impact of Polyarnine-Polyamine Conjugates (20 M) on Uptake of 
Non-Polyarnine Amino Acids in Cultured Pulmonary 
Artery Smooth Muscle Cells 
PERCENT CONTROL UPTAKE 
Amino Acid Put—Put Spd-Spd Spm-Sprn 
MAIBA* 
25PM 106:4 ll4i5 1261*5 
501M 103 i 6 106 i 5 H7 1'" l2 
Lysine 
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TABLE 2A-continued 
Impact of Polyamine-Polyamine Conjugates (20 M) on Uptake of 
N on-Polyamine Amino Acids in Cultured Pulmonary 
Artery Smooth Muscle Cells 
PERCENT CONTROL UPTAKE 
Amino Acid Put-Put Spd—Spd Spm-Spm 
2.5 M 105 i 4 103 i 13 99 i 11 
*MAIBA: methylaminoisobutyric acid 
TABLE 2B 
Impact of Polyamine-BSA Conjugates (20 M) on Uptake of 
Non-Polyamine Amino Acids in Cultured Pulmonary 
Artery Smooth Muscle Cells 
PERCENT CONTROL UPTAKE 
Amino Acid Put-Put Spd-Spd Spm-Spm 
MA1BA* 
2.5uM 121 i2 1151-6 l98i8 
5.0 M 126 i 10 120 i 7 129 i ll 
Lysine 
2.5uM ll3il8 lOOiS 109i8 
*MAIBA: methylaminoisobutyric acid 
These results demonstrate that neither the polyarnine 
polyamine conjugates or the polyarnine-BSA conjugates 
impaired the uptake of these two amino acids. Thus, this 
provides further evidence that the subject polyarnine trans 
port inhibitors are selective for inhibiting polyarnine trans 
port. This is further supported by the fact that even within 
the different polyarnine conjugates there are variable e?°ects 
on uptake of the di?erent polyarnines, e.g., Put-Put and 
Put-BSA inhibited the uptake of putrescine but not spermine 
or sperrnidine. 
EXAMPLE 5 
Determination as to Whether the Subject Polyamine 
Conjugates are Intemalized by Treated Cells 
The inventors considered the possibility that the subject 
inhibitors do not block polyarnine transport, but rather 
merely substitute for the naturally-occurring polyarnines and 
are thereby transported into the cell where they may exert 
some biological activity. However, this was considered 
highly improbable given that the molecular weight of the 
subject conjugates which for both classes of inhibitors is 
respectively in excess of 15,000 and 65,000 daltons. 
Two strategies were devised to determine whether the 
conjugates internalized into the cell or remained con?ned to 
the cell surface. In the ?rst experiment, the inventors made 
use of their previous observation that the operation of the 
polyamine transporter is temperature sensitive. At low tem 
perature the transporter is inoperative and polyarnines asso 
ciated with the cell are bound non-speci?cally to the mem 
brane. Thus, it was reasoned that if the subject inhibitors 
access the cell interior via the polyamine transporter, then 
there should be substantial di?erences between the cell 
content of the inhibitors at normal and low—temperaturev 
conditions. Therefore, radioactive polyarnine-polyamine 
conjugates were synthesized using radioactive polyamines 
(analogous to the method for assessing polyamine uptake in 
the previous examples). After incubation of pulmonary 
artery smooth muscle cells with the radioactive labelled 
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polyamine-polyarnine conjugates at 4° and 37° C., the 
cell-associated radioactivity was then determined. In accord 
with the inventors’ expectations, there were no discernable 
di?erences in the content of cell-associated radioactivity 
between cells at low and normal temperature (data not 
shown). 
Also, a second experiment was conducted to determine 
whether the inhibitors internalize cells using confocal 
microscopy, using methods such as an described in Fisher et 
al, Nucl. Acids Res., 21, 3857-3865, 1993; Petroll et al, J. 
Microsc. 170, 213-219, 1993; and Schipper et al, Exp. Cell 
Res., 207, 62—67, 1993. The BSA portion of a spermine-BSA 
conjugate was labelled with the ?uorescent molecule 
rhodamine and confocal. Microscopy was then used to 
determine the cellular localization of the conjugate. 
This technique examines the cells much like a CAT scan 
examines the human body. Essentially, the microscope takes 
pictures of discrete sections through the vertical dimension 
of a cell, the uppermost of which comprises the cell mem 
brane, whereas a mid-level picture would likely capture the 
cell nucleus, etc. Using this technique, it was found (results 
not shown) that all of the cell ?uorescence was localized to 
the cell membrane and that no ?uorescence would be 
detected in any interior portion of the cell. 
Based on both the temperature-dependent experiments 
and the ?uorescence studies using confocal microscopy, it is 
believed by the present inventors that the subject polyamine 
transport inhibitors act at the level of the cell membrane and 
do not access the cell interior. 
EXAMPLE 6 
Biological Eifects of the Subject Polyarnine 
Inhibitors 
In order to determine the biological effects of the subject 
inhibitors on cells, several experiments were conducted. For 
example, it was observed that treatment of pulmonary artery 
smooth muscle cells with 30 M of the subject conjugates 
did not result in exclusion of the vital stain tryptan blue. This 
provides further evidence that the conjugates are not overtly 
toxic. 
Also, the effects of Spm-Spm on the induction of 
?bronectin synthesis by hypoxic in pulmonary artery 
smooth muscle cells was determined. This experiment was 
e?’ected because hypoxic pulmonary hypertension is accom 
panied by the deposition of large quantities of ?bronectin 
around pulmonary arteries. Therefore, there is some belief 
by researchers, including the present inventors, that the 
increased deposition of this protein may be an important 
cause of the sustained elevation in pulmonary arterial blood 
pressure. Also, hypoxia seems to cause pulmonary hyper 
tension by a mechanism related to increased polyarnine 
transport rather than increased de novo polyarnine synthesis. 
The availability of the subject polyarnine transport inhibi 
tors therefore provided an opportunity to test the hypothesis 
that hypoxia evokes synthesis and release of a pathologi 
cally-relevant protein by a polyarnine transport-dependent 
mechanism. 
The results of this experiment are contained in Table 3. 
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TABLE 4A 
Impact of DFMO and Spm-Spm Conjugate on Hypoxia-induced 
Fibronectin Synthesis in Cultured Pulmonary 
Impact of Spm-Spm Conjugate on Vinblasn'ne Uptake by Drug 
sensitive (MESSE) and Drug-resistant (DXE) 
Artery Smooth Muscle Cells 5 Human Bladder Cancer Cells in Culture 
Fibroneetin Synthesis (OD/mg protein) vinblastine Uptake (dprn/30 min/pg protein) 
Exptl. DFMO + Cell Type Control +20 M Spm-Spm 
Group Control DFMO Spm-Sprn Sprn 
MESSE 9.7 i 0.3 13 i 0.3 
Normoxic 0.08 0.07 0.05 0.04 10 DXE 10 i 0.2 14 i 0.1 
Hypoxic 0.12 0.09 0.06 0.05 
In the control (non-hypoxic cells), inhibitors of de novo TABLE 4B 
1 ' nth i ' FMO f '1 reduce eu po yalimne Sy es s ‘.mt.h D al ed to. the ac Impact of Spm—Spm Conjugate on Vinblastine Uptake by Drug 
mulation of ?bronectrn 1n the culture medium. By contrast, 15 
inhibition of polyamine transport with the Spm-Spm con 
jugate resulted in a substantial reduction of accumulation of 
?bronectin which was not suppressed by the addition of 
DFMO. This is consistent with the inventors’ belief that de 
novo synthesis of polyarnines is not involved in the response 
to hypoxia. Moreover, the results indicate that the Spm-Spm 
conjugate prevent a biological response (increased ?bronec 
tin accumulation) believed to be strongly involved in 
hypoxic pulmonary hypertension. 
Also, the e?’ects of the subject polyamine inhibitors using 
the transport of an anti-tumor drug (viablastine) by cultured 
human bladder cancer cells was examined. It is known that 
cancer cells express a specialized membrane pump called 
the “Multiple Drug Resistance” (MDR) transporter. This 
comprises a therapeutically signi?cant system since it 
enables tumor cells to become resistant to anti-tumor drugs 
by pumping an anti-tumor drug out of the cell interior. 
One MDR transporter has been identi?ed by previous 
researchers which comprises 12 discrete domains that span 
the cell membrane. Only about a half dozen of such 12-do 
main membrane spanning type proteins are known in the art, 
with one being the putrescine transporter isolated from 
bacteria. Accordingly, the present inventors postulated that 
the MDR pump and the polyamine transport system may be 
functionally related, particularly given the fact that both 
transport systems are highly expressed in tumor cells. 
To test this hypothesis, experiments were conducted to 
determine whether or not inhibitors of the MDR transporter 
would decrease polyamine uptake and, conversely, if inhi— 
bition of polyamine import with the subject polyamine 
conjugates would attenuate the MDR pathway, thereby 
increasing the cellular content of anti-tumor drugs. 
In the ?rst study, the effects of two‘agents known to inhibit 
the MDR, i.e., veraparnil and cyclosporin, on polyamine 
transport by cultured pulmonary artery smooth muscle cells 
was assessed. The results obtained indicate that both agents 
suppress polyamine transport by about 50-75% (data not 
shown). 
In the second study, culture of the above-noted MESSE 
and DXE human bladder cancer cells were treated with 
Spm-Spm and the tumor cell content of the anti-cancer drug 
vinblastine was then measured. 
As shown in Table 4A set forth below, Spm~Spm provided 
modest, but signi?cant increases in the tumor cell content of 
vinblastine. The data contained in Table 4B, set forth on the 
following page, on the further suggest that the effect of 
Spm-Spm on the retention of vinblastine by tumor cells is 
dramatically more pronounced when the cells are rendered 
hypoxic (a condition which may mimic that of cells com 
prised in the center of a solid tumor). This may be explained 
by the presence of another type of MDR transport system. 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
sensitive (MESSE) and Drug-resistant (DXE) 
Human Bladder Cells Cultured in an Hypoxic Environment 
vinblastine Uptake (dprn/30 min/pg protein) 
Cell Type Control 1 20 PM Spm-Spm 
MESSE 6.2 i 0.6 8.3 i 0.7 
DXE 3.2 i 0.7 8.3 i 1.3 
These results are extremely exciting since they provide 
further evidence regarding the link between the MDR and 
polyamine transport pathways. Also, they expand the poten 
tial utility of the subject polyamine transport inhibitors as 
anti-neoplastic agents. In particular, administration of the 
subject inhibitors to cancer subjects should prevent cancer 
cells by inhibiting uptake of polyarnines required for abnor 
mal cell proliferation. 
Also, when the subject inhibitors are administered in 
conjunction with anti—cancer agents they should enhance 
their efficiency by preventing their MDR-driven export from 
tumor cells. 
EXAMPLE 7 
Effect of Polyarnine~conjugates on Cultured 
Cultured Human Uterine Sarcoma and Leukemia 
cells1 
Cytotoxicity was assessed using the MTT assay in MES 
SA and DX5 uterine sarcoma cell lines after a 24 hours 
exposure to ascending concentrations of the putrescine poly 
meric conjugates (poly~PUT conjugates) or its vehicle. As 
shown in FIG. 5, the poly-PUT conjugate evoked concen 
tration-dependent lethality in MES-SA and DX5 cells. Con 
centrations of poly-PUT associated with 50% cytotoxicity 
(IC50) were 60:12 and 200i20 M in MES—SA and DX5 
cells, respectively. The cytotoxic effects of a polymeric 
conjugate of sperrnine (poly-8PM), which suppresses trans 
port of all three polyarnines in smooth muscle cells, in both 
MES-SA and DX5 cells as well as K567 Human leukemia 
cells and their MDR-positive variants R7 cells are shown in 
Table 5. Similar to the impact of poly-PUT, poly-SPM also 
is cytotoxic in both cancer cells lines, with the MDR 
positive variants being slightly more resistant. There are at 
least several interesting aspects regarding these observa 
tions. First, they demonstrate that the polyamine-conjugates 
exhibit antineoplastic activity in two human cancer cells 
lines. Second, the ?nding that the SPD-conjugate is some 
what more potent than the PUT conjugate is consistent with 
previous data indicating that the former is more effective in 
blocking polyamine uptake in bovine pulmonary artery 
smooth muscle cells (PASMCs). Further studies with the 
SPM-conjugate are planned since this compound appears to 
be the most potent polyamine transport inhibitor in pulmo 
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nary artery smooth muscle cells (PASMCs) by virtue of its 
activity against both of the putative uptake pathways. 
Finally, the nearly 3-fold difference in sensitivity between 
DX5 and MES-SA cells suggests that the presence of the 
MDR transporter could be’ a determinant of polyamine 
transport activity and the attendant sensitivity of cancer cells 
to killing by polyamine transport inhibitors. This will be 
addressed in further research. 
The Conjugate Concentrations for experiments 7—l3 were determined based 
on the molecular weight of free polyarnines and not the molecular weight of 
the conjugates. For example, Poly-SPM concentrations would be 71 times 
lower if they were determined based on molecular weight of Poly-SPM (25 
KDa) rather than SPM which is around 350. 
TABLE 5 
Poly-SPM conjugate Cytotoxicity in Parental and MDR cells 
Cell Line IC50 (pM) Resistance 
MES-SA 37 i 10 4.5-fold 
170 i 4.0 
K567 43 i 5 
R7 137 i 20 32-fold 
EXAMPLE 8 
Polyamine Conjugates Inhibit Polyamine Uptake 
and Reduce Cell Polyamine Contents in Human 
Cancer Cells 
Additional studies were conducted to determine whether 
MES-SA and DX5 cell 'lines express a polyamine transport 
system, and, if so, whether this system(s) was inhibited by 
the poly-PUT and poly-SPM conjugate. We focused our 
e?orts on comparisons between the PUT and SPM conju 
gates because these compounds appeared to discriminate 
between the selective and nonselective pathways in bovine 
pulmonary artery smooth muscle cells. In the current stud 
ies, 14C-SPD was added in concentrations of 3 M and cells 
were incubated for 30 minutes at selected temperatures (4° 
and 37° C). The cells were rinsed with Hanks buffer, 
digested for 1 hour in 1N NaOH, and cell-associated radio 
activity was deterrnined. 1“C-SPD uptake rate was normal 
ized to protein content. Speci?c, carrier-mediated polyamine 
uptake was calculated subtracting the total polyamine 
uptake, detemiined at 37° C., from the non-speci?c 
polyamine burden determined at 40° C. As shown in Table 
6 MES-SA and DXS express a polyantine transport system 
as evidenced by substantial temperature-dependent 
polyamine accumulation. Addition of 20 pM SPM-SPM 
conjugate reduced polyamine transport in MES-SA and DX5 
cells by 10 and 3 fold, respectively. These results indicate 
that the polyamine conjugates are effective in blocking 
polyamine transport in uterine sarcoma cells, which is 
consistent with our previous experience in bovine PASMCs. 
It also is noteworthy that the uptake of SPD, as assessed at 
a single concentration (3 M), is substantially less in the 
DX5 cell line(li0.03) than in control (5.5i0.35). The rea 
sons for this are unclear, but it is hypothesized that the 
presence of the MDR confers greater resistance to 
polyamine uptake blockade by promoting compensatory 
increases in the activity of de novo pathways of polyamine 
synthesis. 
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TABLE 6 
Impact of poly-PUT and poly-SPM Conjugates on “C-SPD 
Uptake by MDR-negative (MES-SA) and MDR-positive (DXS) 
Human Uterine Sarcoma Cells in Culture 
% Speci?c Spermidine Uptake 
Cell Line Control +20 M poly-PUT +20 1.1M poly-SPM 
MES-SA 100 84 i 2.4 15.6 i 0.6 
DXS 100 57 i 3.3 6.2 i 0.13 
EXAMPLE 9 
E?ect of Polyamine Conjugates or Polyamine 
Transport By Human Leukemia Cells 
K567 leukemia cells and their MDR positive variant were 
suspended at a density of 25x104 cells/n11 in serum free 
medium. 1 M of 1‘*C-SPD was added and the cells were 
incubated at 37° C. for 30 minutes. Incubation was termi 
nated by rapidly chilling the cells on ice followed by 
centrifugation of 6000 RPM for 5 minutes at 4° C. The cells 
were washed in ice-cold Tris buffer and centrifugated. The 
pellet was lysed for 1 hour in 1N NaOH, and cell accumu 
lated radioactivity was detemrined. 1‘iC-SPD uptake rate 
was normalized to protein content. Both the K567 human 
leukemia cell line and its MDR positive variant R7 
expressed the polyamine transport system as shown in Table 
7. Presence of 20 pM poly-SPM almost completely blocked 
polyamine transport in K567 cells and its MDR variant R7. 
TABLE 7 
Impact of poly-SPM Conjugates on 1‘*C-SPD Uptake 
by MDR-negative (K567) and MDR-positive (R7) 
Human Leukemia Cell Lines 
Speci?c Spermidine Uptake 
Pmole/min/mg protein 
Cell Line Control +20 |.tM poly-SPM 
K567 77.3 i 1.5 0.7 i 0.03 
K567/R7 27.0 i 0.5 0.73 i 0.09 
EXAMPLE 10 
To determine if the cytotoxicity and inhibition of 
polyamine transport evoked by the polyamine conjugates 
was,associated with depletion of cell polyamine contents, 
additional experiments were conducted which used HPLC to 
measure contents of PUT, SPD, and SPM in human uterine 
sarcoma and leukemia cells in the presence of poly-SPM, 
DFMO, and combined treatment with poly-SPM and 
DFMO. The latter combination was tested to determine if 
blockade of both transport and synthesis would promote 
greater decreases in polyarrtine content than either interven 
tion alone. As shown in Table 8, poly-SPM was eifective in 
decreasing contents‘ of all polyarnines in all cells, while 
DFMO caused modest depletion of SPD but not SPM. This 
is a signi?cant enlightening observation; numerous reports 
have commented that DFMO fails to reduce SPM levels, and 
this has been invoked as an additional explanation of the 
relatively unimpressive cytotoxicity of DFMO. Indeed, 
DFMO at 1 mM concentration was not toxic to either 
MES-SA or K562 cells or their MDR-positive variants. By 
contrast, poly-SPM, which decreases SPM contents along 
with the other polyamines is highly toxic to all cells. It was 
also observed that the e?’ect of poly-SPM+DFMO in com 
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bination on cell polyarnine contents tended to be greater than 
either agent alone, thus highlighting the interactive roles of 
transport and synthesis in governing polyamine contents. 
Further studies are planned to obtain further information 
26 
Making use of the fact that vinblastine is a well known 
substrate for the MDR transporter, we reasoned that if 
polyamine uptake blockade suppressed MDR activity, then 
this should be re?ected as a decrease in the resistance of 
regardiilg. mteracnons betwfien thase paihways ‘(ind thfm 5 MDR-positive cells to vinblastine-induced killing in concert 
surtabrlrties as pharmacologic targets. It rs potentially sig- . . . . . 
. . . with an increase in the cellular retention of the alkaloid. The 
m?cant that the impact of poly-SPM on polyamrne contents MTT d t ff th Ic f . b1 t. 
in the MDR-positive cells was somewhat less impressive aésfiy ‘was use 0 qua“ 1 y e _ 50 or vm as me 
than in the parental lines_ This ?nding may haw implica_ cytotoxrcrty in MES-SA and DX5 cells in the presence and 
tions for mechanisms by which polyamine transport and 10 absence of treatment Wlth 100 PM Poly-PUT The calcula 
MDR activity are interactive processes, tion of cytotoxicity in these experiments accounted for the 
lethality associated with use of the conjugate alone. As 
TABLE 8 shown in Table 9, DX5 cells were resistant to vinblastine 
Cellular Polyamine content (moles/mg protein) in cytotoxicity relative to the parental MES-SA cells and 
MDR-negative (MES-SA, K562) and MDR-positive 15 retained less vinblastine. The PUT-conjugate had little effect 
(Dxi K562/R7) Human Cancer Cells on the lC5O for vinblastine cytotoxicity in MES-SA, but 
Treatment PUT SPD SPM PUT SPD 5PM caused a 60-fold decrease in the MDR-positive DX5 line. 
MES SA DX5 Similarly, while the baseline vinblastine content in DX5 
- 20 cells was, as expected, less than in MES-SA cells, the 
Control 2172 11913 6477 1195 9685 6202 conjugate increased drug retention in the MDR-negative 
DFMO (1 mM) ND 6100 8824 ND 4191 6831 cells by a mere 50% while vinblastine retention was 
Poly-SPM 722 6845 4368 ND 7496 6089 _ _ _ _ _ 
(20 PM) mcreased over 200% in the MDR-positive line. These ?nd 
PQIY-SPM + ND 3477 4167 ND 5136 5635 ings provide pharmacologic evidence that the MDR pathway 
DFMO K562 16mm 25 and polyarnine transport are functionally interactive in this 
human uterine sarcoma cell line. Similar results were gen 
gggglu mM) 5133131 @913? 12321 61?? @333 gig? erated with the use of another substrate of MDR transporter, 
PO1y_SPM ND 3234 2384 1042 6133 4779 Taxol. Treatment with 100 M poly-SPM increased the 
(20 11M) 30 accumulation of Taxol in DX5 cells, but not MES-SA. 
ggégpM + ND 2412 2312 ND 2142 1793 Poly-SPM also caused a decrease in IC50 for Taxol in DX5 
without signi?cant effect on MDR-negative MES-SA cell 
line (data not shown). 
TABLE 9 
Impact of Poly-PUT Conjugate on vinblastine Cytotoxicity 
and Uptake by MDR-negative (MES-SA) and MDR<positive (DX5) 
Human Uterine Sarcoma Cells 
1“C-Vinblastrine Content 
IC50 (11M) (dpm/30/min/ug protein) 
Cell Line Control +100 11M PUT-Conjugate Control +100 uM PUT—Conjugate 
MES-SA .005 .007 6.2 i 0.6 8.3 i 0.7 
DX5 0.6 .116 3.2 i 0.7 8.3 i 1.3 
Collectively, these ?ndings indicate that the cytotoxicity EXAMPLE 12 
of polyarnine conjugates in human tumor cells is associated 
with depressed transmembrane polyamine transport and 
decreased cell polyamine contents. It is therefore reasonable 
to conclude that the decreased cell polyarnine content is the 
proximate mechanism of cytotoxic action of the polyamine 
conjugates. We also have observed interesting di?’erences in 
the impact of polyarnine transport blockade and kinetics of 
polyarnine transport between MDR-positive and -negative 
cell lines, which suggest that there exist pharrnacologically 
signi?cant interactions between these transport systems. 
EXAMPLE ll 
Modulation of MDR Activity by Polyamine 
Transport and Synthesis Inhibition in Human 
Uterine Sarcoma Cells 
Complimentary experiments were conducted to determine 
whether the polyarnine uptake inhibitors differentially 
affected the cytotoxicity and cellular uptake of vinblastine in 
MDR-negative and MDR-positive uterine sarcoma cells. 
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Effect of DFMO on Polyamine Transport in 
MDR-negative (MES-SA) and MDR-positive 
(DX5) Human Uterine Sarcoma Cells 
In many cells, DFMO increases polyarnine transport. This 
is believed to be a compensatory mechanism that protects 
these cells from polyamine depletion. Indeed, in the pre 
liminary studies described supra, DFMO was less e?ective 
than transport blockade in reducing cell polyamines and in 
causing cell death. The present invention accordingly con 
cluded that the induction of transport by DFMO would be a 
useful strategy for further experiments. Indeed, if MDR 
activity is linked to polyamine transport rate, then the 
actions of DFMO on MDR activity should be opposite to 
those of the transport inhibitors, despite the fact that both 
DFMO and the transport inhibitors have qualitatively similar 
effects on cell polyamine contents. In other words, while 
polyaminc conjugates decrease MDR activity, DFMO 
5,456,908 
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should promote an increase in activity which reduces cyto 
toxic drug content and decreases drug-induced lethality. We 
therefore examined the impact of DFMO on polyamine 
transport rate and on vinblastine accumulation and cytotox 
icity in MES-SA and DX5 cells. As shown in Table 10, it 
was found that 24 hours’ treatment with DFMO caused 
slight increases in both PUT and SPD transport rate in DX5 
cells but, surprisingly, not in MES-SA cells. These results 
suggest that cells expressing the MDR phenotype exhibit a 
DEMO-inducible polyamine transporter that may not be 
present in MDR-negative cells. 
TABLE 10 
E?tect of DFMO on Polyamine Transport in MDR-negative 
(MES-SA) and MDR-positive (DX5) Human Uterine 
Sarcoma Cells 
1“ C-Polyamine uptake (pmoles/rnin/mg protein) 
CONTROL 
PUT DFMO (1 mM) 
Cell Line SPD SPD PUT 
MES-SA 0.7 i 0.06 7.6 i 0.2 0.67 i 0.01 7.3 i .06 
DX5 0.8 i 0.05 1.4 i 0.2 1.1 i 0.04 1.6 i .08 
EXAMPLE 13 
Eifect of DFMO on Vinblastine Accumulations in 
MDR~negative (MES-SA) and MDR-positive 
(DX5) Human Uterine Sarcoma Cells 
DFMO, as predicted, decreased vinblastine accumulation 
in DX5 cells but not in the parental line, MES-SA (Table 11). 
In a companion study, MES-SA cells exhibited the expected 
sensitivity to vinblastine relative to DX5, characterized by 
IC50 values of 0.005 M and 0.5 M, respectively. Impor 
tantly, DFMO treatment failed to affect the IC5o value for 
vinblastine in MES-SA cells but engendered complete resis 
tance in DX5 cells to vinblastine, at least in concentrations 
up to 5 uM. Thus, DFMO which increases polyamine 
transport in DX5 cells also appears to increase MDR activity 
and render MDR-positive cells even more resistant to the 
cytotoxic eifects of vinblastine. 
TABLE 11 
E?’ect of DPMO on Vinblastine Accumulation in MDR-negative 
(MES-SA) and MDR-positive (DX5) Human Uterine 
Sarcoma Cells 
3I-I-Virtblastine Content (pmoles/mg protein) 
Cell Line CONTROL DFMO (1 mM) 
MES-SA 825 i 20 840 i 28 
DX5 290 i 10 195 i 8 
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What is claimed is: 
1. A method for inhibiting the cellular uptake of a 
polyamine or polyamines comprising contacting cells which 
are capable of actively transporting said polyamine or 
polyamines with a transport inhibitory e?iective amount of 
an inhibitor which comprises a polymer or copolymer 
wherein the repeating units comprise said polyamine or 
polyamines. 
2. The method of claim 1 wherein the repeating units of 
the transported substance are covalently attached by a cou 
pling agent. 
3. The method of claim 2 wherein the coupling agent is 
glutaraldehyde. 
4. The method of claim 1 wherein said polymer or 
copolymer comprises a polyamine selected from the group 
consisting of putrescine, spermine and spermidine. 
5. The method of claim 1 wherein said polymer of the 
transported substance comprises a molecular weight ranging 
from 15,000 to 100,000 daltons. 
6. The method of claim 1 wherein the polymer of the 
transported substance is further attached to a moiety which 
provides for the selective targeting of the inhibitor to cells 
which uptake the transported substance. 
7. The method of claim 4 wherein said copolymer com 
prises different polyamines. 
8. The method of claim 4 wherein the molecular weight of 
said polyamine polymer ranges from about 15,000 to 100, 
000 daltons. 
9. The method of claim 4 wherein the treated cells 
comprise tumor cells or pulmonary artery smooth muscle 
cells. 
10. The method of claim 9 wherein said cells are further 
contacted with a substance which inhibits the synthesis of 
polyamines. 
11. The method of claim 10 wherein said substance is 
d-di?uoro-methylomithine. 
12. The method of claim 9 wherein said cells comprise 
tumor cells which are further contacted with an anti-tumor 
agent, and the e?icacy of said anti-tumor agent is assessed 
in relation to control tumor cells which are contacted with 
said anti-tumor agent but which cells are not contacted with 
the inhibitor. 
13. The method of claim 1 wherein said contacting is 
effected in vitro in a cell culture medium which contains 
cells which are capable of uptaking said polyamine or 
polyamines by active transport. 
14. The method of claim 13 wherein said cells are human 
tumor cells. 
15. The method of claim 10 wherein the polyamine 
synthesis inhibiting substance is a substance which inhibits 
omithine decarboxylase. 
